Metastasis is the principal cause of cancer death and occurs through multiple, complex processes that involve the concerted action of many genes. A number of studies have indicated that the Fragile Histidine Triad (FHIT) gene product, FHIT, functions as a tumor suppressor in a variety of common human cancers. Although there are suggestions of a role for FHIT loss in progression of various cancers, a role for such loss in metastasis has not been defined. Here, via in vivo and in vitro assays, we reveal that the enforced expression of FHIT significantly suppresses metastasis, accompanied by inhibition of the epithelial-mesenchymal transition (EMT), a process involved in metastasis through coordinate modulation of EMT-related genes. Specifically, miR-30c, a FHIT-upregulated microRNA, contributes to FHIT function in suppression of EMT and metastasis by directly targeting metastasis genes Metadherin (MTDH), High-mobility group AT—hook 2 (HMGA2), and the mesenchymal markers, Vimentin (VIM) and Fibronectin (FN1), in human lung cancer. Finally, we demonstrate that the expression pattern of FHIT and miR-30c is inversely correlated with that of MTDH and HMGA2 in normal tissue, non-metastatic and metastatic tumors, serving as a potential biomarker for metastasis in lung cancer. Although Fragile Histidine Triad (FHIT) is known as a potential tumor suppressor gene in terms of tumor initiation and progression, the role of FHIT in the metastatic process is not well characterized. Here it is shown that FHIT reduces the motility and invasiveness of lung cancer cells in vitro and ability to metastasize in vivo, at least partially through the miR-30c-mediated suppression of EMT, a critical process during tumor metastasis. This study provides new insights into the role of FHIT and a FHIT-activated miRNA, miR-30c, as crucial modulators in lung metastasis.